|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
Cancers in 185 Countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar
|
|
2
|
Wu K, Li L, Thakur C, Lu Y, Zhang X, Yi Z
and Chen F: Proteomic characterization of the world trade center
dust-activated mdig and c-myc signaling circuit linked to multiple
myeloma. Sci Rep. 6:363052016. View Article : Google Scholar
|
|
3
|
Zhang Y, Lu Y, Yuan BZ, Castranova V, Shi
X, Stauffer JL, Demers LM and Chen F: The Human mineral
dust-induced gene, mdig, is a cell growth regulating gene
associated with lung cancer. Oncogene. 24:4873–4882. 2005.
View Article : Google Scholar
|
|
4
|
Sun J, Yu M, Lu Y, Thakur C, Chen B, Qiu
P, Zhao H and Chen F: Carcinogenic metalloid arsenic induces
expression of mdig oncogene through JNK and STAT3 activation.
Cancer Lett. 346:257–263. 2014. View Article : Google Scholar
|
|
5
|
Thakur C, Wolfarth M, Sun J, Zhang Y, Lu
Y, Battelli L, Porter DW and Chen F: Oncoprotein mdig contributes
to silica-induced pulmonary fibrosis by altering balance between
Th17 and Treg T cells. Oncotarget. 6:3722–3736. 2015. View Article : Google Scholar
|
|
6
|
Tsuneoka M, Koda Y, Soejima M, Teye K and
Kimura H: A novel myc target gene, mina53, that is involved in cell
proliferation. J Biol Chem. 277:35450–35459. 2002. View Article : Google Scholar
|
|
7
|
Eilbracht J, Kneissel S, Hofmann A and
Schmidt-Zachmann MS: Protein NO52-a constitutive nucleolar
component sharing high sequence homologies to protein NO66. Eur J
Cell Biol. 84:279–294. 2005. View Article : Google Scholar
|
|
8
|
Chowdhury R, Sekirnik R, Brissett NC,
Krojer T, Ho CH, Ng SG, Clifton LJ, Ge W, Kershaw NJ, Fox GC, et
al: Ribosomal oxygenases are structurally conserved from
prokaryotes to humans. Nature. 510:422–426. 2014. View Article : Google Scholar
|
|
9
|
Aziz N, Hong YH, Jo M, Kim JK, Kim KH,
Ashktorab H, Smoot DT, Hur H, Yoo BC and Cho AJY: Molecular
signatures of JMJD10/MINA53 in gastric cancer. Cancers.
12:11412020. View Article : Google Scholar
|
|
10
|
Ge W, Wolf A, Feng T, Ho CH, Sekirnik R,
Zayer A, Granatino N, Cockman ME, Loenarz C and Loik ND:
Oxygenase-catalyzed ribosome hydroxylation occurs in prokaryotes
and humans. Nat Chem Biol. 8:960–962. 2012. View Article : Google Scholar
|
|
11
|
Zhang Q, Thakur C, Shi J, Sun J, Fu Y,
Stemmer P and Chen F: New discoveries of mdig in the epigenetic
regulation of cancers. Semin Cancer Biol. 57:27–35. 2019.
View Article : Google Scholar
|
|
12
|
Komiya K, Sueoka-Aragane N, Sato A,
Hisatomi T, Sakuragi T, Mitsuoka M, Sato T, Hayashi S, Izumi H,
Tsuneoka M and Sueoka E: Mina53, a novel c-Myc target gene, is
frequently expressed in lung cancers and exerts oncogenic property
in NIH/3T3 cells. J Cancer Res Clin Oncol. 136:465–473. 2010.
View Article : Google Scholar
|
|
13
|
Thakur C, Lu Y, Sun J, Yu M, Chen B and
Chen F: Increased expression of mdig predicts poorer survival of
the breast cancer patients. Gene. 535:218–224. 2014. View Article : Google Scholar
|
|
14
|
Zhang L, Huo Q, Ge C, Zhao F, Zhou Q, Chen
X, Tian H, Chen T, Xie H, Cui Y, et al: ZNF143-mediated H3K9
trimethylation upregulates CDC6 by activating MDIG in
hepatocellular carcinoma. Cancer Res. 80:2599–2611. 2020.
View Article : Google Scholar
|
|
15
|
Teye K, Tsuneoka M, Arima N, Koda Y,
Nakamura Y, Ueta Y, Shirouzu K and Kimura H: Increased expression
of a Myc target gene Mina53 in human colon cancer. Am J Pathol.
164:205–216. 2004. View Article : Google Scholar
|
|
16
|
Xing J, Wang K, Liu PW, Miao Q and Chen
XY: Mina53, a novel molecular marker for the diagnosis and
prognosis of gastric adenocarcinoma. Oncol Rep. 31:634–640. 2014.
View Article : Google Scholar
|
|
17
|
Bellut J, Bertz S, Nolte E, Stöhr C,
Polifka I, Lieb V, Herrmann E, Jung R, Hartmann A, Wullich B, et
al: Differential prognostic value of MYC immunohistochemistry in
subtypes of papillary renal cell carcinoma. Sci Rep. 7:164242017.
View Article : Google Scholar
|
|
18
|
Kuratomi K, Yano H, Tsuneoka M, Sakamoto
K, Kusukawa J and Kojiro M: Immunohistochemical expression of
Mina53 and Ki67 proteins in human primary gingival squamous cell
carcinoma. Kurume Med J. 53:71–78. 2006. View Article : Google Scholar
|
|
19
|
Teye K, Arima N, Nakamura Y, Sakamoto K,
Sueoka E, Kimura H and Tsuneoka M: Expression of myc target gene
mina53 in subtypes of human lymphoma. Oncol Rep. 18:841–848.
2007.
|
|
20
|
Thakur C and Chen F: Current understanding
of mdig/MINA in human cancers. Genes Cancer. 6:288–302. 2015.
View Article : Google Scholar
|
|
21
|
Komiya K, Sueoka-Aragane N, Sato A,
Hisatomi T, Sakuragi T, Mitsuoka M, Sato T, Hayashi S, Izumi H,
Tsuneoka M and Sueoka E: Expression of Mina53, a novel c-Myc target
gene, is a favorable prognostic marker in early stage lung cancer.
Lung Cancer. 69:232–238. 2010. View Article : Google Scholar
|
|
22
|
Yu M, Sun J, Thakur C, Chen B, Lu Y, Zhao
H and Chen F: Paradoxical roles of mineral dust induced gene on
cell proliferation and migration/invasion. PLoS One. 9:e879982014.
View Article : Google Scholar
|
|
23
|
Thakur C, Chen B, Li L, Zhang Q, Yang ZQ
and Chen F: Loss of mdig expression enhances DNA and histone
methylation and metastasis of aggressive breast cancer. Signal
Transduct Target Ther. 3:252018. View Article : Google Scholar
|
|
24
|
Wang Q, Geng F, Zhou H, Chen Y, Du Y,
Zhang X, Song D and Zhao H: MDIG promotes cisplatin resistance of
lung adenocarcinoma by regulating ABC transporter expression via
activation of the WNT/β-catenin signaling pathway. Oncol Lett.
18:4294–4307. 2019.
|
|
25
|
Xuan F, Huang M, Zhao E and Cui H: MINA53
deficiency leads to glioblastoma cell apoptosis via inducing DNA
replication stress and diminishing DNA damage response. Cell Death
Dis. 9:10622018. View Article : Google Scholar
|
|
26
|
Zhou H, Geng F, Chen Y, Du J, Zhang X, Liu
B, Song D, Hou H and Zhao H: The mineral dust-induced gene, mdig,
regulates angiogenesis and lymphangiogenesis in lung adenocarcinoma
by modulating the expression of VEGF-A/C/D via EGFR and HIF-1α
signaling. Oncol Rep. 45:602021. View Article : Google Scholar
|
|
27
|
GTEx Consortium: The genotype-tissue
expression (GTEx) project. Nat Gen. 45:580–585. 2013. View Article : Google Scholar
|
|
28
|
The TCGA Legacy: Cell. 173:281–282. 2018.
View Article : Google Scholar
|
|
29
|
Wang S, Xiong Y, Zhao L, Gu K, Li Y, Zhao
F, Li J, Wang M, Wang H, Tao Z, et al: UCSCXenaShiny: An R/CRAN
Package for interactive analysis of UCSC xena data. Bioinformatics.
38:527–529. 2021. View Article : Google Scholar
|
|
30
|
Gao J, Aksoy BA, Dogrusoz U, Dresdner G,
Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al:
Integrative analysis of complex cancer genomics and clinical
profiles using the cBioPortal. Sci Signal. 6:112013. View Article : Google Scholar
|
|
31
|
Chandrashekar DS, Bashel B, Balasubramanya
SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK and
Varambally S: UALCAN: A portal for facilitating tumor subgroup gene
expression and survival analyses. Neoplasia. 19:649–658. 2017.
View Article : Google Scholar
|
|
32
|
Massó-Vallés D, Beaulieu ME and Soucek L:
MYC, MYCL, and MYCN as therapeutic targets in lung cancer. Expert
Opin Ther Targets. 24:101–114. 2020. View Article : Google Scholar
|
|
33
|
Huang CL, Yokomise H and Miyatake A:
Clinical significance of the p53 pathway and associated gene
therapy in non-small cell lung cancers. Future Oncol. 3:83–93.
2007. View Article : Google Scholar
|
|
34
|
Chen B, Khodadoust MS, Liu CL, Newman AM
and Alizadeh AA: Profiling tumor infiltrating immune cells with
CIBERSORT. Methods Mol Biol. 1711:243–259. 2018. View Article : Google Scholar
|
|
35
|
Ju M, Jiang L, Wei Q, Yu L, Chen L, Wang
Y, Hu B, Qian P, Zhang M, Zhou C, et al: A immune-related signature
associated with TME can serve as a potential biomarker for survival
and sorafenib resistance in liver cancer. Onco Targets Ther.
14:5065–5083. 2021. View Article : Google Scholar
|
|
36
|
Zeng D, Li M, Zhou R, Zhang J, Sun H, Shi
M, Bin J, Liao Y, Rao J and Liao W: Tumor microenvironment
characterization in gastric cancer identifies prognostic and
immunotherapeutically relevant gene signatures. Cancer Immunol Res.
7:737–750. 2019. View Article : Google Scholar
|
|
37
|
Meyers DE and Banerji S: Biomarkers of
immune checkpoint inhibitor efficacy in cancer. Curr Oncol.
27(Suppl 2): S106–S114. 2020.
|
|
38
|
Ru B, Wong CN, Tong Y, Zhong JY, Zhong
SSW, Wu WC, Chu KC, Wong CY, Lau CY, Chen I, et al: TISIDB: An
integrated repository portal for tumor-immune system interactions.
Bioinformatics. 35:4200–4202. 2019. View Article : Google Scholar
|
|
39
|
Mariathasan S, Turley SJ, Nickles D,
Castiglioni A, Yuen K, Wang Y, Kadel EE III, Koeppen H, Astarita
JL, Cubas R, et al: TGFβ attenuates tumour response to PD-L1
blockade by contributing to exclusion of T cells. Nat. 554:544–548.
2018. View Article : Google Scholar
|
|
40
|
Yang W, Soares J, Greninger P, Edelman EJ,
Lightfoot H, Forbes S, Bindal N, Beare D, Smith JA, Thompson IR, et
al: Genomics of drug sensitivity in cancer (GDSC): A resource for
therapeutic biomarker discovery in cancer cells. Nucleic Acids Res.
41:D955–D961. 2013. View Article : Google Scholar
|
|
41
|
Geeleher P, Cox N and Huang RS:
pRRophetic: An R package for prediction of clinical
chemotherapeutic response from tumor gene expression levels. PLoS
One. 9:e1074682014. View Article : Google Scholar
|
|
42
|
Geeleher P, Cox NJ and Huang RS: Clinical
drug response can be predicted using baseline gene expression
levels and in vitro drug sensitivity in cell lines. Genome Biol.
15:R472014. View Article : Google Scholar
|
|
43
|
Hänzelmann S, Castelo R and Guinney J:
GSVA: Gene set variation analysis for microarray and RNA-seq data.
BMC Bioinformatics. 14:72013. View Article : Google Scholar
|
|
44
|
Powers RK, Goodspeed A, Pielke-Lombardo H,
Tan AC and Costello JC: GSEA-InContext: Identifying novel and
common patterns in expression experiments. Bioinformatics.
34:i555–i564. 2018. View Article : Google Scholar
|
|
45
|
Choucair K, Morand S, Stanbery L, Edelman
G, Dworkin L and Nemunaitis J: TMB: A promising immune-response
biomarker, and potential spearhead in advancing targeted therapy
trials. Cancer Gene Ther. 27:841–853. 2020. View Article : Google Scholar
|
|
46
|
Bouchez C, Kempf E and Tournigand C: MSI
Metastatic solid tumors treatment and immunotherapies. Bull Cancer.
106:143–150. 2019. View Article : Google Scholar
|
|
47
|
Kaur J, Elms J, Munn AL, Good D and Wei
MQ: Immunotherapy for non-small cell lung cancer (NSCLC), as a
stand-alone and in combination therapy. Crit Rev Oncol Hematol.
164:1034172021. View Article : Google Scholar
|
|
48
|
Yu JS and Cui W: Proliferation, survival
and metabolism: The role of PI3K/AKT/mTOR signalling in
pluripotency and cell fate determination. Development.
143:3050–3060. 2016. View Article : Google Scholar
|
|
49
|
Ferreira MJ, Pires-Luís AS, Vieira-Coimbra
M, Costa-Pinheiro P, Antunes L, Dias PC, Lobo F, Oliveira J,
Gonçalves CS, Costa BM, et al: SETDB2 and RIOX2 are differentially
expressed among renal cell tumor subtypes, associating with
prognosis and metastization. Epigenetics. 12:1057–1064. 2017.
View Article : Google Scholar
|
|
50
|
Shi J, Thakur C, Zhao Y, Li Y, Nie L,
Zhang Q, Bi Z, Fu Y, Wadgaonkar P, Almutairy B, et al: Pathological
and prognostic indications of the mdig gene in human lung cancer.
Cell Physiol Biochem. 55:13–28. 2021. View Article : Google Scholar
|
|
51
|
Tan XP, Dong WG, Zhang Q, Yang ZR, Lei XF
and Ai MH: Potential effects of Mina53 on tumor growth in human
pancreatic cancer. Cell Biochem Biophys. 69:619–625. 2014.
View Article : Google Scholar
|
|
52
|
Kulis M and Esteller M: DNA methylation
and cancer. Adv Genet. 70:27–56. 2010. View Article : Google Scholar
|
|
53
|
Arneth B: Tumor microenvironment. Medicina
(Kaunas). 56:152019. View Article : Google Scholar
|
|
54
|
Mori T, Okamoto K, Tanaka Y, Teye K, Umata
T, Ohneda K, Tokuyama K, Okabe M and Tsuneoka M: Ablation of Mina53
in mice reduces allergic response in the airways. Cell Struct
Funct. 38:155–167. 2013. View Article : Google Scholar
|
|
55
|
Pillai MR, Mihi B, Ishiwata K, Nakamura K,
Sakuragi N, Finkelstein DB, McGargill MA, Nakayama T, Ayabe T,
Coleman ML and Bix M: Myc-induced nuclear antigen constrains a
latent intestinal epithelial cell-intrinsic anthelmintic pathway.
PLoS One. 14:e02112442019. View Article : Google Scholar
|
|
56
|
Chen T, Yang C, Dou R and Xiong B:
Identification of a novel 10 immune-related genes signature as a
prognostic biomarker panel for gastric cancer. Cancer Med.
10:6546–6560. 2021. View Article : Google Scholar
|
|
57
|
Yamada N, Oizumi S, Kikuchi E, Shinagawa
N, Konishi-Sakakibara J, Ishimine A, Aoe K, Gemba K, Kishimoto T,
Torigoe T and Nishimura M: CD8+ tumor-infiltrating lymphocytes
predict favorable prognosis in malignant pleural mesothelioma after
resection. Cancer Immunol Immunother. 59:1543–1549. 2010.
View Article : Google Scholar
|
|
58
|
Pilard C, Ancion M, Delvenne P, Jerusalem
G, Hubert P and Herfs M: Cancer immunotherapy: It's time to better
predict patients' response. Br J Cancer. 125:927–938. 2021.
View Article : Google Scholar
|
|
59
|
Postow MA, Sidlow R and Hellmann MD:
Immune-related adverse events associated with immune checkpoint
blockade. N Engl J Med. 378:158–168. 2018. View Article : Google Scholar
|
|
60
|
Gibney GT, Weiner LM and Atkins MB:
Predictive biomarkers for checkpoint inhibitor-based immunotherapy.
Lancet Oncol. 17:e542–e551. 2016. View Article : Google Scholar
|
|
61
|
Nowak RP, Tumber A, Hendrix E, Ansari MSZ,
Sabatino M, Antonini L, Andrijes R, Salah E, Mautone N, Pellegrini
FR, et al: First-in-class inhibitors of the ribosomal oxygenase
MINA53. J Med Chem. 64:17031–17050. 2021. View Article : Google Scholar
|
